The Rise and Fall of Vioxx

This chapter explores the rushed development and approval of Vioxx by Merck amidst competition and safety concerns. It highlights the company's questionable practices in conducting insufficient studies and manipulating data to downplay cardiovascular risks. Additionally, the chapter addresses the broader implications of corporate influence in the pharmaceutical industry, illustrated through the extensive marketing strategy employed for Vioxx.